Home › Funds › Versant Venture Management, LLC › GLUE
Versant Venture Management, LLC position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
Versant Venture Management, LLC reported holding 3,180,780 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$37.9M, representing 34.78% of its reported portfolio and ranking #1 among its reported holdings. Versant Venture Management, LLC has disclosed GLUE holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Versant Venture Management, LLC's GLUE position evolved
Versant Venture Management, LLC first disclosed a stake in GLUE in Q4 2024 at 5,652,922 shares (US$39.2M). The position peaked in Q2 2026 at 3,180,780 shares, worth US$77.0M. Across 8 filings, Versant Venture Management, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 3,180,780 shares valued at US$37.9M. Notable position changes include a 27% trim in Q1 2026 (shares rose 47% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 5.65M | $39.23M | New |
| Q1 2025 | 5.65M | $26.23M | Hold |
| Q2 2025 | 5.65M | $25.49M | Hold |
| Q3 2025 | 5.65M | $41.89M | Hold |
| Q4 2025 | 4.38M | $68.72M | Reduce |
| Q1 2026 | 3.18M | $52.32M | Reduce |
| Q2 2026 | 3.18M | $76.97M | Hold |
| Q3 2026 | 3.18M | $37.95M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 62 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $111.86M · Q2 2026
- Vestal Point Capital, LP 4.60M sh · $111.32M · Q2 2026
- BVF INC/IL 4.46M sh · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026
- Aisling Capital Management LP 1.56M sh · $18.56M · Q3 2026
- Nextech Invest Ltd. 761.15K sh · $18.42M · Q2 2026
More on Versant Venture Management, LLC
FAQ
How long has Versant Venture Management, LLC held GLUE?
Versant Venture Management, LLC has disclosed GLUE holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Versant Venture Management, LLC's current position in GLUE?
As of Q3 2026, Versant Venture Management, LLC holds 3.18M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $37.95M, representing 34.78% of its reported portfolio and ranking #1.
Has Versant Venture Management, LLC been buying or selling GLUE?
In the latest 13F filing (Q3 2026), Versant Venture Management, LLC held unchanged its position in GLUE. The position peaked in Q2 2026 at 3.18M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, Vestal Point Capital, LP, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.